Logo image of SRDX

SURMODICS INC (SRDX) Stock News

NASDAQ:SRDX - Nasdaq - US8688731004 - Common Stock - Currency: USD

29.01  +0.01 (+0.03%)

After market: 29.01 0 (0%)

SRDX Latest News, Press Relases and Analysis

News Image
19 days ago - Zacks Investment Research

QuidelOrtho (QDEL) Down 18% Since Last Earnings Report: Can It Rebound?

QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mentions: QDEL

News Image
26 days ago - Zacks Investment Research

Why Is SurModics (SRDX) Up 6% Since Last Earnings Report?

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mentions: BSX

News Image
2 months ago - Zacks Investment Research

Are Options Traders Betting on a Big Move in Surmodics Stock?

Investors need to pay close attention to SRDX stock based on the movements in the options market lately.

News Image
2 months ago - Zacks Investment Research

SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts

Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics' second-quarter fiscal 2025 results show weak performance.

Mentions: BSX ITGR EHC

News Image
2 months ago - Zacks Investment Research

SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

News Image
a year ago - BusinessInsider

SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q3 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Surmodics (NASDAQ:SRDX) just reported results for the third quarter of 2024.Sur...

News Image
a year ago - InvestorPlace

SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q3 2024

SRDX stock results show that Surmodics beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2024.